-
Mashup Score: 11Slow down your giddyup on Gilead news - 4 year(s) ago
Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment This is what STAT reported in what they labeled an “Exclusive” last evening. Other news organizations played copycat, adding caveats Fox News picked up on the STAT story, but added its own caveats: “Partial data from an ongoing clinical trial is …
Source: HealthNewsReview.orgCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 11Slow down your giddyup on Gilead news - 4 year(s) ago
Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment This is what STAT reported in what they labeled an “Exclusive” last evening. Other news organizations played copycat, adding caveats Fox News picked up on the STAT story, but added its own caveats: “Partial data from an ongoing clinical trial is …
Source: HealthNewsReview.orgCategories: CardiologistsTweet-
RT @CaulfieldTim: "Slow down your giddyup on #Gilead news" https://t.co/YxzN430JL8 by @garyschwitzer via @HealthNewsRevu with @VPrasadMDMPH…
-
-
Mashup Score: 5Slow down your giddyup on Gilead news - 4 year(s) ago
Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment This is what STAT reported in what they labeled an “Exclusive” last evening. Other news organizations played copycat, adding caveats Fox News picked up on the STAT story, but added its own caveats: “Partial data from an ongoing clinical trial is …
Source: HealthNewsReview.orgCategories: Hem/OncsTweet-
RT @CaulfieldTim: "Slow down your giddyup on #Gilead news" https://t.co/YxzN430JL8 by @garyschwitzer via @HealthNewsRevu with @VPrasadMDMPH…
-
-
Mashup Score: 3Slow down your giddyup on Gilead news - 4 year(s) ago
Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment This is what STAT reported in what they labeled an “Exclusive” last evening. Other news organizations played copycat, adding caveats Fox News picked up on the STAT story, but added its own caveats: “Partial data from an ongoing clinical trial is …
Source: HealthNewsReview.orgCategories: Healthcare ProfessionalsTweet-
"Slow down your giddyup on #Gilead news" https://t.co/YxzN430JL8 by @garyschwitzer via @HealthNewsRevu with @VPrasadMDMPH @venkmurthy @jeremyfaust #COVID10 Yep. "Thus far, preliminary statements regarding uncontrolled studies haven’t withstood further scrutiny very well."
-
-
Mashup Score: 0
“Did remdesivir just ‘solve’ COVID? No,” says Umer Raffat, an analyst at Evercore ISI.
Source: MarketWatchCategories: Healthcare ProfessionalsTweet-
Why an analyst bullish on #Gilead says #antiviral drug ‘won’t solve’ COVID-19 - MarketWatch: $GILD https://t.co/LlsbCik7gv
-
-
Mashup Score: 1Gilead takes a hit after quietly terminating a closely-watched Covid-19 trial of remdesivir - 4 year(s) ago
Shares of Gilead took a 3% hit $GILD Wednesday after the big biotech noted that it had suspended one of its closely-watched Covid-19 studies for remdesivir in China. Initially highlighted in a note from RBC Capital, Gilead stated in an update on clinicaltrials.gov today that their Phase III for mild
Source: Endpoints NewsCategories: Healthcare ProfessionalsTweet-
UPDATED: #Gilead takes a hit after a closely-watched Covid-19 trial of #remdesivir is quietly terminated, raising fresh doubts - https://t.co/qmwv7rLSFd
-
-
Mashup Score: 2
Chinese scientists will soon share results from two trials testing Gilead’s remdesivir as a coronavirus therapy. Here’s what the data could show.
Source: STATCategories: Future of MedicineTweet-
RT @CNSSummit: What you need to know about #Gilead and its potential Covid-19 therapy. https://t.co/np9vrW9V3A #CNSSummit
-
RT @CaulfieldTim: "Slow down your giddyup on #Gilead news" https://t.co/YxzN430JL8 by @garyschwitzer via @HealthNewsRevu with @VPrasadMDMPH…